# EDGAR Filing Document

**Accession Number:** 0001600132
**File Stem:** 0001600132-23-000015
**Filing Date:** 2023-3
**Character Count:** 5015
**Document Hash:** 118004a78338a605fa7b2fbca5b5b717
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001600132-23-000015.hdr.sgml**: 20230303

**ACCESSION NUMBER**: 0001600132-23-000015

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230303

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20230303

**DATE AS OF CHANGE**: 20230303

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Bellerophon Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001600132
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 473116175
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36845
- **FILM NUMBER:** 23705826

**BUSINESS ADDRESS:**
- **STREET 1:** 184 LIBERTY CORNER ROAD, SUITE 302
- **CITY:** WARREN
- **STATE:** NJ
- **ZIP:** 07059
- **BUSINESS PHONE:** 908-574-4770

**MAIL ADDRESS:**
- **STREET 1:** 184 LIBERTY CORNER ROAD, SUITE 302
- **CITY:** WARREN
- **STATE:** NJ
- **ZIP:** 07059

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Bellerophon Therapeutics LLC
- **DATE OF NAME CHANGE:** 20140213

?xml version='1.0' encoding='UTF-8'?

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): March 3, 2023

## Bellerophon Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Delaware** |  | **001-36845** |  | **47-3116175** |
| (State or Other Jurisdiction of Incorporation) |  | (Commission<br>File Number) |  | (IRS Employer<br>Identification No.) |

---

---

| | | |
|:---|:---|:---|
| **184 Liberty Corner Road, Suite 302Warren, New Jersey** |  | **07059** |
| (Address of Principal Executive Offices) |  | (Zip Code) |

---

Registrant's telephone number, including area code: **(908) 574-4770**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| **Common Stock, $0.01 par value per share** | **BLPH** | **The** **Nasdaq** **Capital Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

☐ Emerging growth company <br> ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

------

#### Item 8.01. Other Events.
On March 3, 2023, Bellerophon Therapeutics, Inc. (the "Company") suspended, and is not offering any shares of its common stock pursuant to, the prospectus supplement dated January 19, 2023 relating to the Open Market Sale Agreement, dated as of July 17, 2020 (the "Sales Agreement"), by and between the Company and Jefferies LLC. The Company will not make any sales of common stock pursuant to the Sales Agreement unless and until a new prospectus supplement is filed with the SEC; however, the Sales Agreement remains in full force and effect.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, which is being made only by means of a written prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, nor shall there be any sale of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction..

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | BELLEROPHON THERAPEUTICS, INC. | BELLEROPHON THERAPEUTICS, INC. |
| Date: March 3, 2023 | By: | /s/ Peter Fernandes |
|  |  | Name: Peter Fernandes<br>Title: Chief Executive Officer |

---